Chugai Seiyaku KK
4519
ISIN JP3519400000 / Valor 761611
Chugai Seiyaku KK
UMushroom community rating:
About company
Chugai Seiyaku KK is a research-based pharmaceutical company that specializes in the development, production, and marketing of prescription medicines, with a strong focus on biopharmaceuticals and molecular targeted therapies. The company emphasizes the importance of safety and regulatory compliance, having established an independent Drug Safety Division to ensure the secure and appropriate use of its products globally. Chugai's Quality & Regulatory Compliance Unit oversees the adherence to pharmaceutical regulations and maintains the integrity of its quality management system through rigorous audits and a global IT system. The company prioritizes high-value R&D projects and actively secures intellectual property rights, including lifecycle patents and innovative drug discovery technologies. Chugai collaborates closely with the Roche Group for global co-development, aiming to bring innovative medicines to market efficiently and effectively.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (14.08.2024):
Revenue Decline
In the second quarter of FY2024, Chugai Seiyaku KK reported a revenue of ¥552.9 billion, marking a 4.6% decrease year on year. This decline was primarily attributed to a reduction in sales, despite an increase in other revenue streams.
Operating Profit Increase
Chugai Seiyaku KK's operating profit for the same period saw a significant increase, reaching ¥258.2 billion. This represents a 22.4% rise compared to the previous year, showcasing improved operational efficiency and cost management.
Net Income Growth
The net income for Chugai Seiyaku KK in FY2024 Q2 was ¥186.3 billion, an 18.9% increase year on year. This growth in net income reflects the company's strong financial performance despite the challenges in revenue.
Core Operating Profit
Chugai Seiyaku KK's core operating profit for the first half of FY2024 was ¥262.8 billion, which is a 13.3% increase year on year. This improvement was driven by a favorable product mix and increased efficiency in operations.
FY2024 Outlook
For the full fiscal year 2024, Chugai Seiyaku KK projects revenues to decrease by 3.7% to ¥1,070.0 billion. However, core operating profit is expected to rise by 2.1% to ¥460.0 billion, and core net income is anticipated to grow by 0.6% to ¥335.5 billion, indicating a positive outlook despite revenue challenges.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
69362 M
Market cap (USD)
1,627,200
Daily traded volume (Shares)
6510 / 6370
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
